Influenza

2016 Review of the PIP Framework

The PIP Advisory Group met in a Special Session on 13-14 October 2015 to seek views from Member States, industry and other stakeholders on the 2016 PIP Framework Review. The Advisory Group recommended that a small independent group of experts be established to review implementation of the PIP Framework using a transparent and inclusive approach.

The Review will focus on answering the following questions:

  • What are the achievements since the PIP Framework was adopted?
  • Has implementation of the PIP Framework improved global pandemic influenza preparedness, including interpandemic surveillance, and capacity to respond?
  • What are the challenges, and possible ways of addressing them?

Further details on the scope and terms of reference for the 2016 Review may be found in paragraphs 14-19 of the Report of the Special Session of the PIP Advisory Group.

It is expected that the Review Group will provide its final Report to the Director-General by October 2016, so that it may be considered by the Executive Board in January 2017 and the World Health Assembly in May 2017.

During the second consultative session with Member States and stakeholders on 29 August 2016, the Review Group discussed their preliminary, draft findings. Their feedback will be taken into consideration for the report that will be submitted to DG in October 2016 and available under EB documents ahead of EB140, January 2017.

These preliminary findings are still under consideration by the Review Group and may be revised in the final report.

Comments or questions to the review group should be addressed directly to: PIPreviewcomments@workspace.who.int.

Review Group questions for Member States and Stakeholders

The Review Group invites Member States and stakeholders to respond to the following questions, or to share their views on any other aspects of the implementation of the PIP Framework, to the following email address: PIPreviewcomments@workspace.who.int.

Please note that all who provide input to the Review Group will be acknowledged in the final report, however, all such input will be considered confidential and will not be published, or shared outside the Review Group, or attributed, without the express permission of the contributor.

Questions to Member States

  • Has the PIP Framework helped better prepare Member States for a pandemic? How could this capacity be improved?
  • What are the key challenges in the implementation of the PIP Framework? What are possible ways to overcome these challenges?
  • Are the principles underpinning the PIP Framework, e.g. transparency, fairness, equity, efficiency, and virus sharing and benefit sharing on an equal footing, being implemented?
  • How should the PIP Framework ensure it remains relevant and effective?
  • Have there been any collateral benefits (i.e. benefits beyond the initial intent) arising from implementation of the PIP Framework? If so what are these benefits?
  • What views do Member States have on using the PIP Framework as a model for sharing of other pathogens?
  • How well is the work of the PIP Framework communicated to Member States?
  • How do Member States view their interaction with the PIP Framework Secretariat? How could this interaction be strengthened?

Questions to Stakeholders

  • Has the PIP Framework helped better prepare the world for a pandemic? How could this capacity be improved?
  • What are the key challenges in the implementation of the PIP Framework? What are possible ways to overcome these challenges?
  • Are the principles underpinning the PIP Framework, e.g. transparency, fairness, equity, efficiency, and virus sharing and benefit sharing on an equal footing, being implemented?
  • How should the PIP Framework ensure it remains relevant and effective?
  • Have there been any collateral benefits (i.e. benefits beyond the initial intent) arising from implementation of the PIP Framework? If so what are these benefits?
  • How could the PIP Framework be used as a model for sharing of other pathogens?
  • How well is the work of the PIP Framework communicated to you?
  • How do you view your interaction with the PIP Framework Secretariat? How could this interaction be strengthened?

Notice to Stakeholders

All stakeholders are reminded that contact with the Review Group or its members should take place only through established channels during Review Group meetings or through the Review Group mailbox PIPreviewcomments@workspace.who.int.

Stakeholders are kindly asked to respect this principle that ensures the integrity of the Review Group, its membership and its processes and proceedings. Any Review Group member contacted directly by any stakeholder should remind the stakeholder of this notice.

Advance copies of Nagoya Study and PIP Review Report

Following translation of the Executive Summary of the Nagoya study and the PIP Review Report these documents will be available on the EB140 website.

TORS for a study on public health implications of the Nagoya Protocol

  • TORs
    pdf, 311kb

    Terms of Reference for study on how the implementation of the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity might affect the sharing of pathogens and the potential public health implications.

Contact details

Contact the Secretariat:
pipreview@who.int

Open invitation for submissions

The PIP Framework Review Group welcomes submissions at any time at PIPreviewcomments@workspace.who.int